(Integral Molecular) Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4 million by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders, including obesity and metabolic syndrome. With this Phase 2 SBIR grant, Integral Molecular builds on its successful Phase 1 SBIR program isolating antibodies with high specificity and high affinity for CB1.
from EurekAlert! - Technology, Engineering and Computer Science https://ift.tt/2u08PiL
Tuesday, March 12, 2019
Integral Molecular's MAbs against CB1 to treat NASH enter new development phase following $1.4 million award
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.